[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0609093A8 - Processo para preparar uma cepa de bifidobacterium sp. que contém um gene tetw mutante em seu cromossomo, cepa de bifidobacterium e uso da mesma - Google Patents

Processo para preparar uma cepa de bifidobacterium sp. que contém um gene tetw mutante em seu cromossomo, cepa de bifidobacterium e uso da mesma

Info

Publication number
BRPI0609093A8
BRPI0609093A8 BRPI0609093A BRPI0609093A BRPI0609093A8 BR PI0609093 A8 BRPI0609093 A8 BR PI0609093A8 BR PI0609093 A BRPI0609093 A BR PI0609093A BR PI0609093 A BRPI0609093 A BR PI0609093A BR PI0609093 A8 BRPI0609093 A8 BR PI0609093A8
Authority
BR
Brazil
Prior art keywords
bifidobacterium
strain
antibiotic
strains
sensitive
Prior art date
Application number
BRPI0609093A
Other languages
English (en)
Inventor
Stroman Per
Original Assignee
Chr Hansen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05010216A external-priority patent/EP1724340B1/en
Application filed by Chr Hansen As filed Critical Chr Hansen As
Publication of BRPI0609093A2 publication Critical patent/BRPI0609093A2/pt
Publication of BRPI0609093A8 publication Critical patent/BRPI0609093A8/pt
Publication of BRPI0609093B1 publication Critical patent/BRPI0609093B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

LINHAGENS DE BACTÉRIAS DE ÁCIDO LÁCTICO SENSÍVEIS A ANTIBIÓTICOS. Muitas Bifidobacteriaceas probjóticas contêm um tetW ativo que torna as células resistentes à tetraciclina. Isto pode apresentar um risco de transferência horizontal de genes antibióticos funcionais. A presente invenção refere-se a um processo de obtenção de novas cepas sensíveis à tetraciclina do gênero de Bifidobacteriacea (Bifidobacterium sp.). Em particular, a presente invenção refere-se a novas cepas sensíveis a antibióticos obtidas partindo de cepas resistentes a antibióticos e ao uso de tais novas cepas para a preparação de um alimento ou de um produto alimentício ou uma forma de dosagonde compreende organismos viáveis.
BRPI0609093A 2005-05-11 2006-05-11 processo para preparar uma cepa de bifidobacterium sp. que contém um gene tetw mutante em seu cromossomo, cepa de bifidobacterium e uso da mesma BRPI0609093B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05010216.9 2005-05-11
EP05010216A EP1724340B1 (en) 2005-05-11 2005-05-11 Antibiotic-sensitive lactic acid bacteria strains
DKPA200600267 2006-02-24
DKPA200600267 2006-02-24
PCT/DK2006/050020 WO2006119780A2 (en) 2005-05-11 2006-05-11 New antibiotic-sensitive lactic acid bacteria strains

Publications (3)

Publication Number Publication Date
BRPI0609093A2 BRPI0609093A2 (pt) 2010-02-17
BRPI0609093A8 true BRPI0609093A8 (pt) 2018-07-31
BRPI0609093B1 BRPI0609093B1 (pt) 2018-12-18

Family

ID=37084645

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0609093A BRPI0609093B1 (pt) 2005-05-11 2006-05-11 processo para preparar uma cepa de bifidobacterium sp. que contém um gene tetw mutante em seu cromossomo, cepa de bifidobacterium e uso da mesma

Country Status (5)

Country Link
US (2) US8021883B2 (pt)
EP (3) EP1882034A2 (pt)
BR (1) BRPI0609093B1 (pt)
RU (1) RU2394911C2 (pt)
WO (1) WO2006119780A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1882034A2 (en) 2005-05-11 2008-01-30 Chr. Hansen A/S New antibiotic-sensitive lactic acid bacteria strains
EP2057266B2 (en) * 2006-08-18 2017-06-21 Nestec S.A. Genetic remodeling in bifidobacterium
WO2008058854A1 (en) * 2006-11-15 2008-05-22 Chr. Hansen A/S New tetracycline-sensitive bifidobacteria strains
PL2318511T3 (pl) * 2008-08-28 2018-01-31 Chr Hansen As Kompozycja bakteryjna
WO2010023178A1 (en) * 2008-08-28 2010-03-04 Chr. Hansen A/S Pharmaceuticals comprising a bacterial polysaccharide
US9462817B2 (en) 2011-02-28 2016-10-11 Franklin Foods Holdings Inc. Processes for making cheese products utilizing denatured acid whey proteins
US9635870B2 (en) 2011-02-28 2017-05-02 Franklin Foods Holdings Inc. Direct-set cheese
ES2625632T3 (es) 2013-07-04 2017-07-20 Abm Technologies, Llc Método para la determinación rápida de la susceptibilidad o de la resistencia de las bacterias a los antibióticos
EP3048174B1 (en) 2015-01-21 2018-11-07 ABM Technologies, LLC Procedure for the rapid determination of bacterial susceptibility to antibiotics that inhibit protein synthesis
CN110016448A (zh) * 2019-04-24 2019-07-16 上海海洋大学 一种快捷分离筛选抑菌性乳酸菌的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3479157D1 (en) 1984-04-03 1989-08-31 Biodisk Ab Method and device for producing varying concentration patterns of chemically or biologically active substances
EP0768375B2 (fr) 1992-07-06 2002-06-12 Societe Des Produits Nestle S.A. Bactérie lactique
DE69322166T2 (de) 1992-08-28 1999-04-22 The Trustees Of Tufts College, Medford, Mass. Prüfung auf ein vielfache resistenz gegen antibiotika verursachendes operon
US6063613A (en) 1993-12-06 2000-05-16 The Rockefeller University Auxiliary genes and proteins of methicillin resistant bacteria and antagonists thereof
AT405235B (de) 1995-11-02 1999-06-25 Helmut Dr Viernstein Probiotisch wirksame formulierung
US5945285A (en) 1996-06-27 1999-08-31 President And Fellows Of Harvard College Vibrio cholerae having increased sensitivity to antibiotics
BR9811332A (pt) 1997-08-21 2000-09-19 New Zealand Dairy Board Bactérias de ácido lático intensificadoras de imunidade
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
EP1320594A2 (en) 2000-09-30 2003-06-25 E.I. Du Pont De Nemours And Company Exbb-exbd-tonb gene cluster of pseudomonas putida dot-t1e conferring tolerance to aromatic compounds and resistance to antibiotics
WO2003097813A2 (en) 2002-05-17 2003-11-27 Microbia, Inc. Regulation of staphylococcus aureus biofilm formation
EP1364586A1 (en) 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
KR20110038739A (ko) 2002-06-25 2011-04-14 가부시키가이샤 아데카 β글루칸 함유 유지 조성물 및 β글루칸을 생산하는 신규 미생물
EP1882034A2 (en) 2005-05-11 2008-01-30 Chr. Hansen A/S New antibiotic-sensitive lactic acid bacteria strains
PL1724340T3 (pl) 2005-05-11 2009-08-31 Chr Hansen As Szczepy bakterii kwasu mlekowego wrażliwe na antybiotyk

Also Published As

Publication number Publication date
EP2194125A2 (en) 2010-06-09
WO2006119780A2 (en) 2006-11-16
RU2394911C2 (ru) 2010-07-20
EP1882034A2 (en) 2008-01-30
EP2264164A1 (en) 2010-12-22
BRPI0609093B1 (pt) 2018-12-18
WO2006119780A3 (en) 2007-06-21
RU2007145713A (ru) 2009-06-20
US8440450B2 (en) 2013-05-14
US8021883B2 (en) 2011-09-20
EP2194125A3 (en) 2012-07-18
US20080171073A1 (en) 2008-07-17
US20120045820A1 (en) 2012-02-23
BRPI0609093A2 (pt) 2010-02-17

Similar Documents

Publication Publication Date Title
BRPI0609093A8 (pt) Processo para preparar uma cepa de bifidobacterium sp. que contém um gene tetw mutante em seu cromossomo, cepa de bifidobacterium e uso da mesma
Slomka et al. Nutritional stimulation of commensal oral bacteria suppresses pathogens: the prebiotic concept
Briaud et al. Coexistence with Pseudomonas aeruginosa alters Staphylococcus aureus transcriptome, antibiotic resistance and internalization into epithelial cells
Mason et al. Candida albicans and bacterial microbiota interactions in the cecum during recolonization following broad-spectrum antibiotic therapy
Valiente et al. The Clostridium difficile PCR ribotype 027 lineage: a pathogen on the move
Weiss et al. Lactobacillus acidophilus induces virus immune defence genes in murine dendritic cells by a Toll‐like receptor‐2‐dependent mechanism
Claesson et al. Multireplicon genome architecture of Lactobacillus salivarius
Douillard et al. Comparative genomic analysis of the multispecies probiotic-marketed product VSL# 3
AU2018225255A1 (en) Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof
Cuaron et al. Tea tree oil‐induced transcriptional alterations in Staphylococcus aureus
Panda et al. Structure and functions of the gut microbiome
Ohtani et al. Identification of a two-component VirR/VirS regulon in Clostridium perfringens
Dwidar et al. Indole negatively impacts predation by B dellovibrio bacteriovorus and its release from the bdelloplast
Barketi-Klai et al. The flagellin FliC of Clostridium difficile is responsible for pleiotropic gene regulation during in vivo infection
Biot et al. Interplay between three RND efflux pumps in doxycycline-selected strains of Burkholderia thailandensis
Lorenz et al. Genome sequencing and comparative genomics of enterohemorrhagic Escherichia coli O145: H25 and O145: H28 reveal distinct evolutionary paths and marked variations in traits associated with virulence & colonization
Lopes et al. Microbiome in cystic fibrosis: shaping polymicrobial interactions for advances in antibiotic therapy
Novović et al. Acinetobacter spp. porin Omp33-36: Classification and transcriptional response to carbapenems and host cells
Baron et al. Inactivation of the arn operon and loss of aminoarabinose on lipopolysaccharide as the cause of susceptibility to colistin in an atypical clinical isolate of proteus vulgaris
Lee et al. A novel peptide nucleic acid against the cytidine monophosphate kinase of S. aureus inhibits staphylococcal infection in vivo
Xing et al. Disequilibrium in chicken gut microflora with avian colibacillosis is related to microenvironment damaged by antibiotics
Knowles et al. Genomic tools for customized recovery and detection of foodborne Shiga toxigenic Escherichia coli
Bublitz et al. The natural product chlorotonil A preserves colonization resistance and prevents relapsing Clostridioides difficile infection
Bielaszewska et al. Presence of virulence and fitness gene modules of enterohemorrhagic Escherichia coli in atypical enteropathogenic Escherichia coli O26
Singh et al. In search of novel protein drug targets for treatment of Enterococcus faecalis infections

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A23C 9/123 (2006.01), A23L 29/00 (2016.01), A23L 3

B15K Others concerning applications: alteration of classification

Ipc: C12N 15/01 (2006.01), C12N 1/20 (2006.01), A61K 35

B15K Others concerning applications: alteration of classification

Ipc: C12N 15/01 (2006.01), A23L 33/135 (2016.01), A23C

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/12/2018, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2670 DE 08-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.